Apogee Therapeutics, Inc. APGE
We take great care to ensure that the data presented and summarized in this overview for Apogee Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in APGE
Top Purchases
Top Sells
About APGE
Insider Transactions at APGE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 22
2026
|
Fairmount Funds Management LLC Director |
SELL
Open market or private sale
|
Indirect |
1,750,000
-85.42%
|
$133,000,000
$76.3 P/Share
|
|
Jan 14
2026
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-0.28%
|
$1,620,000
$81.47 P/Share
|
|
Jan 07
2026
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,700
-2.05%
|
$1,458,600
$78.53 P/Share
|
|
Jan 07
2026
|
Carl Dambkowski Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,025
+5.72%
|
$308,550
$22.86 P/Share
|
|
Jan 06
2026
|
Jane Henderson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,000
-1.07%
|
$160,000
$80.0 P/Share
|
|
Jan 02
2026
|
Jane Henderson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,000
-1.56%
|
$444,000
$74.66 P/Share
|
|
Dec 19
2025
|
Jane Henderson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,500
-0.77%
|
$120,000
$80.0 P/Share
|
|
Dec 10
2025
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-0.54%
|
$1,500,000
$75.75 P/Share
|
|
Dec 04
2025
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-3.14%
|
$3,000,000
$75.01 P/Share
|
|
Dec 04
2025
|
Jane Henderson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,500
-0.76%
|
$112,500
$75.0 P/Share
|
|
Dec 04
2025
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,900
-3.87%
|
$817,500
$75.0 P/Share
|
|
Nov 25
2025
|
Jane Henderson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,500
-0.76%
|
$105,000
$70.0 P/Share
|
|
Nov 14
2025
|
Jane Henderson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,000
-1.0%
|
$130,000
$65.0 P/Share
|
|
Nov 13
2025
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-0.39%
|
$1,260,000
$63.37 P/Share
|
|
Nov 11
2025
|
Jane Henderson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,000
-0.5%
|
$60,000
$60.0 P/Share
|
|
Nov 05
2025
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,785
-0.93%
|
$593,175
$55.14 P/Share
|
|
Nov 05
2025
|
Carl Dambkowski Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,060
+2.68%
|
$177,320
$22.86 P/Share
|
|
Oct 01
2025
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,110
-1.76%
|
$199,290
$39.8 P/Share
|
|
Oct 01
2025
|
Carl Dambkowski Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,385
+0.82%
|
$52,470
$22.86 P/Share
|
|
Sep 03
2025
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,725
-0.58%
|
$103,550
$38.18 P/Share
|
Last 12 Months Summary
Buy / Acquisition
41.1K
Shares
From
2
Insiders
| Exercise of conversion of derivative security | 41.1K shares |
|---|
Sell / Disposition
1.97M
Shares
From
4
Insiders
| Open market or private sale | 1.97M shares |
|---|